Try Alerts Free   |   Login
Health Care › Industrial Instruments For Measurement, Display, And Control

DHR Price Correlated With Financials For Danaher

Free historical financial statements for Danaher Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 50 quarters since 2010. Compare with DHR stock chart to see long term trends.

DHR Stock Compared to Quarterly

DHR Income Statement

Revenue, Net:7751000000
Revenue Per Share:10.6551
Cost of Goods & Services Sold:3030000000
Gross Profit:4721000000
Selling, General & Admin Expense:2085000000
Research & Development Expense:431000000
Operating Income:2205000000
Income Taxes:389000000
Net Income:1680000000
Earnings Per Share, Basic:2.28
Shares Outstanding, Basic Avg:727445355

DHR Cash Flow

Operating Activities Net Income:
Change in Accounts Receiveable:225000000
Net Cash from Operations:2000000000
Net Cash from Operations Per Share:2.7493
Cash Dividends Paid:220000000
Net Cash from Financing Activities:-1160000000
Property, Plant & Equipment Purchases:296000000
Purchases of Businesses, Net of Cash:60000000
Net Cash from Investing Activities:-400000000
Net Change in Cash & Equivalents:267000000

DHR Balance Sheet

Cash and Cash Equivalents:3984000000
Accounts Receivable, Net:4527000000
Inventories:3257000000
Total Current Assets:13229000000
Property, Plant & Equipment, Net:3794000000
Total Assets:81806000000
Total Short-Term Liabilities:7556000000
Long Term Debt, Non-Current Portion:20052000000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
52,694,630 sh
1,689,790 sh
3%
$13,359,142
-$1,602,108
Blackrock Inc.
47,556,018 sh
2,128,908 sh
5%
$12,056,402
-$1,268,733
State Street Corp
26,700,019 sh
560,223 sh
2%
$6,775,572
-$898,427
Price T Rowe Associates Inc /Md/
26,443,349 sh
-1,648,652 sh
-6%
$6,703,917
-$1,536,309
FMR LLC
25,510,224 sh
200,947 sh
1%
$6,467,351
-$956,619
Wellington Management Group Llp
18,968,634 sh
891,844 sh
5%
$4,808,928
-$493,537
Morgan Stanley
16,944,511 sh
3,431,423 sh
25%
$4,295,773
$331,976
Massachusetts Financial Services Co /Ma/
11,997,806 sh
-453,806 sh
-4%
$3,041,684
-$610,749
Geode Capital Management, LLC
11,100,164 sh
418,833 sh
4%
$2,808,228
-$316,361
Bank Of America Corp /De/
11,024,205 sh
11,024,205 sh
NEW
$2,794,856
$2,794,856
Capital International Investors
9,144,947 sh
512,330 sh
6%
$2,318,340
-$214,375
Edgewood Management LLC
7,310,111 sh
-817,764 sh
-10%
$1,853,259
-$530,891
Bank Of New York Mellon Corp
7,055,817 sh
184,067 sh
3%
$1,788,790
-$226,901
Royal Bank Of Canada
7,009,184 sh
6,968,484 sh
17122%
$1,776,968
$1,765,029
Jennison Associates LLC
6,977,970 sh
1,333,655 sh
24%
$1,769,055
$113,408
Franklin Resources Inc
6,130,002 sh
207,761 sh
4%
$1,554,077
-$183,133
Aristotle Capital Management, LLC
5,478,344 sh
-83,500 sh
-2%
$1,392,224
-$240,512
Janus Henderson Group Plc
4,794,256 sh
-443,464 sh
-8%
$1,215,465
-$320,915
Legal & General Group Plc
4,656,373 sh
279,432 sh
6%
$1,180,485
-$103,404
Amundi
4,649,220 sh
432,144 sh
10%
$1,157,183
-$102,789
COMPANY PROFILE
BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business —Danaher Corporation (“Danaher” or the “Company”) designs, manufactures and markets professional, medical, industrial and commercial products and services, which are typically characterized by strong brand names, innovative technology and major market positions. As of December 31, 2021, the Company operates in three business segments:

• The Life Sciences segment offers a broad range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines.

• The Diagnostics segment offers clinical instruments, reagents, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

• The Environmental & Applied Solutions segment offers products and services that help protect precious resources and keep global food and water supplies safe. The Company’s water quality business provides instrumentation, consumables, software, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, industrial, waste, ground, source and ocean water in residential, commercial, municipal, industrial and natural resource applications. The Company’s product identification business provides instruments, software, services and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding and traceability applications for consumer, pharmaceutical and industrial products.

Refer to Notes 2 and 3 for a discussion of significant acquisitions, discontinued operations and other dispositions.

Accounting Principles —The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. The Consolidated Financial Statements also reflect the impact of noncontrolling interests. Noncontrolling interests do not have a significant impact on the Company’s consolidated results of continuing operations, therefore earnings attributable to noncontrolling interests for continuing operations are not presented separately in the Company’s Consolidated Statements of Earnings. Earnings attributable to noncontrolling interests have been reflected in selling, general and administrative expenses and were insignificant in all periods presented. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.

Use of Estimates —The preparation of these financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company bases these estimates on historical experience, the current economic environment and on various other assumptions that are believed to be reasonable under the circumstances. However, uncertainties associated with these estimates exist and actual results may differ materially from these estimates.

Cash and Equivalents —The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.

Accounts Receivable and Allowances for Doubtful Accounts —All trade accounts, contract and finance receivables are reported on the accompanying Consolidated Balance Sheets adjusted for any write-offs and net of allowances for doubtful accounts. The allowances

Data imported from Danaher Corp SEC filings. Check original filings before making any investment decision.